P. Yip

发表

Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population

N. Pavlakis, G. Reid, A. Nagrial, 2020, JTO clinical and research reports.

Predictive and prognostic value of circulating tumor cell detection in lung cancer: a clinician's perspective.

T. Becker, V. Bray, W. Chua, 2015, Critical reviews in oncology/hematology.

implications and potential prognostic and predictive biomarkers of the PI3K-Akt-mTOR signaling pathway. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

P. Yip, 2015 .

EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma

S. O'toole, A. Gill, L. Horvath, 2013, Journal of Clinical Pathology.

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab

A. Nagrial, Jenny H. Lee, S. Kao, 2022, Thoracic cancer.

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

J. Madore, R. Scolyer, S. O'toole, 2015, Lung cancer.

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization

S. Fox, B. Solomon, P. Russell, 2013, Modern Pathology.

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

P. Yip, 2015, Translational lung cancer research.

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

P. Yip, 2015 .

Screening for ROS1 gene rearrangements in non‐small‐cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target

N. Pavlakis, S. O'toole, A. Gill, 2017, Histopathology.

Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma

J. Kench, S. O'toole, L. Horvath, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical outcomes in patients with advanced epidermal growth factor receptor‐mutated non‐small‐cell lung cancer in South Western Sydney Local Health District

T. Roberts, T. Becker, J. Descallar, 2017, Internal medicine journal.

Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.

A. Nagrial, Jenny H. Lee, S. Kao, 2022, Asia-Pacific journal of clinical oncology.

Low AZGP1 expression predicts for recurrence in margin‐positive, localized prostate cancer

J. Kench, R. Sutherland, L. Horvath, 2011, The Prostate.

Eastern Cooperative Oncology Group score: Agreement between non-small-cell lung cancer patients and their oncologists and clinical implications

S. Clarke, S. Kao, J. Vardy, 2016 .

Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer

J. Kench, L. Horvath, M. Kohonen-Corish, 2013, Journal of Clinical Pathology.

Outcomes of extensive stage extrapulmonary small cell cancer

F. Hayat, P. Kok, P. Yip, 2022, Internal medicine journal.

Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer

J. Kench, L. Horvath, M. Kohonen-Corish, 2013, Journal of Clinical Pathology.